FoxHollow Believes Extracted Plaque Will Be Vital To PAD Drug Development
This article was originally published in The Gray Sheet
Executive Summary
FoxHollow Technologies plans to sell peripheral artery plaque extracted by itsSilverHawk excision system to pharmaceutical and biotech firms developing new therapies